1. Home
  2. LAC vs DCTH Comparison

LAC vs DCTH Comparison

Compare LAC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

N/A

Current Price

$1.67

Market Cap

686.2M

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$21.91

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LAC
DCTH
Founded
2023
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
686.2M
578.4M
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
LAC
DCTH
Price
$1.67
$21.91
Analyst Decision
Hold
Strong Buy
Analyst Count
12
5
Target Price
$5.07
★ $28.60
AVG Volume (30 Days)
★ 7.5M
528.0K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.21
Revenue
N/A
N/A
Revenue This Year
N/A
$36.66
Revenue Next Year
N/A
$20.12
P/E Ratio
★ N/A
$96.43
Revenue Growth
N/A
N/A
52 Week Low
$1.78
$8.12
52 Week High
$6.96
$21.84

Technical Indicators

Market Signals
Indicator
LAC
DCTH
Relative Strength Index (RSI) 29.45 81.79
Support Level N/A $10.76
Resistance Level $2.22 N/A
Average True Range (ATR) 0.13 0.97
MACD 0.00 0.82
Stochastic Oscillator 1.85 95.13

Price Performance

Historical Comparison
LAC
DCTH

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: